MATP7 Antibody

What is MATP7 Antibody and what are its key specifications?

MATP7 Antibody refers to antibodies targeting the membrane-associated transporter protein (MATP), with the MATP Antibody (7K-2) being a well-characterized example. This specific antibody is a mouse monoclonal IgG2b κ antibody that detects human MATP through applications including western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA) . MATP is a 530 amino acid protein that functions as a transporter, spanning the lipid bilayer 12 times . Its expression is predominantly found in melanoma cell lines but not significantly present in normal tissues, suggesting its potential role in skin cancer research . MATP7 Antibody serves as an invaluable tool for researchers investigating molecular mechanisms underlying melanoma and pigmentation disorders.

How does the target protein MATP function in cellular systems?

MATP functions as a membrane-associated transporter protein primarily expressed in melanocytes and melanoma cells . The protein spans the lipid bilayer 12 times, which is essential for its function as a transporter facilitating the movement of molecules across cellular membranes . MATP expression is transcriptionally regulated by MITF (microphthalmia-associated transcription factor), a melanocyte-specific transcription factor that can influence MATP activity either directly or through remote regulatory sequences . In melanocytes, MATP plays a crucial role in the pigmentation process, as evidenced by the association between MATP gene mutations and albinism . This connection highlights MATP's importance in normal melanin production and distribution. The elevated expression of MATP in melanoma cells compared to normal tissues suggests potential roles in cancer development or progression that warrant further investigation.

What are the recommended applications for MATP7 Antibody in research?

MATP7 Antibody has been validated for multiple research applications, each requiring specific optimization for maximum effectiveness:

For western blotting, researchers should optimize protein extraction using detergent-containing buffers appropriate for membrane proteins. Immunoprecipitation applications benefit from gentler lysis conditions that preserve protein-protein interactions. ELISA applications provide quantitative data but require careful optimization of antibody concentrations and blocking conditions to minimize background signal. In all applications, appropriate positive and negative controls are essential for result validation .

What controls should be included when working with MATP7 Antibody?

Implementing appropriate controls is essential for generating reliable results with MATP7 Antibody. Recent research has demonstrated that knockout (KO) cell lines provide superior control compared to other methods, especially for Western Blots and immunofluorescence imaging . A comprehensive control strategy should include:

• Positive Controls: Melanoma cell lines known to express MATP should be included to confirm antibody functionality and establish expected signal patterns .

• Negative Controls:

  • MATP knockout cell lines (gold standard)

  • Cell types known not to express MATP

  • Isotype control antibody (matched IgG without specific target binding)

• Technical Controls:

  • Secondary antibody-only control to assess background signal

  • Blocking peptide competition assay to confirm specificity

  • Loading controls for Western blots (β-actin, GAPDH)

• Validation Controls:

  • Correlation with mRNA expression data (RT-PCR)

  • Alternative detection methods when possible

Implementing these controls is particularly important given recent findings that approximately 50% of commercial antibodies fail to meet basic standards for characterization, resulting in significant research integrity concerns .

How can researchers validate MATP7 Antibody specificity for critical experiments?

Antibody validation is crucial for research integrity, especially considering that approximately 50% of commercial antibodies fail to meet basic characterization standards, with some studies estimating financial losses of $0.4-1.8 billion per year due to unreliable antibodies . For MATP7 Antibody, implementing a multi-faceted validation approach is recommended:

• Genetic Validation Methods:

  • CRISPR/Cas9 knockout systems provide the most definitive validation, creating cells completely lacking the target protein

  • siRNA knockdown demonstrating proportional reduction in antibody signal

  • Overexpression systems showing increased signal intensity

• Biochemical Validation:

  • Peptide competition assays to confirm epitope specificity

  • Mass spectrometry analysis of immunoprecipitated proteins

  • Sequential immunoprecipitation with alternative MATP antibodies

• Orthogonal Method Validation:

  • Correlation of protein detection with mRNA levels

  • Comparison across multiple detection platforms (WB, IP, IF)

  • Parallel testing with multiple MATP antibodies targeting different epitopes

• Application-Specific Validation:

  • For Western blotting: confirm expected molecular weight and band pattern

  • For immunoprecipitation: verify enrichment of target protein

  • For ELISA: establish standard curves with recombinant protein

Recent studies have demonstrated that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies in validation tests, with higher consistency and lower batch-to-batch variation . Documenting validation steps thoroughly establishes confidence in experimental findings and supports reproducibility.

What methodological approaches ensure optimal Western blot results with MATP7 Antibody?

Western blotting with MATP7 Antibody requires specialized protocols optimized for membrane proteins like MATP. A comprehensive methodological approach includes:

• Sample Preparation:

  • Use membrane protein-specific lysis buffers containing appropriate detergents (e.g., 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS)

  • Include protease inhibitor cocktails to prevent degradation

  • Avoid excessive sonication which may disrupt membrane protein structure

  • Optimize protein concentration (typically 20-50 μg total protein per lane)

• Gel Electrophoresis:

  • Select appropriate acrylamide percentage (typically 8-10% for 530 amino acid MATP protein)

  • Consider gradient gels for better resolution

  • Include molecular weight markers spanning expected MATP size range

• Transfer Optimization:

  • For membrane proteins like MATP, wet transfer systems typically outperform semi-dry methods

  • Consider extended transfer times (90-120 minutes) or overnight transfer at lower voltage

  • Use methanol-containing transfer buffers to facilitate SDS removal from proteins

  • Verify transfer efficiency using reversible stains like Ponceau S

• Antibody Incubation:

  • Test multiple blocking agents (BSA often superior to milk for membrane proteins)

  • Optimize primary antibody dilution through titration experiments

  • Consider extended incubation times (overnight at 4°C) for maximum sensitivity

  • Include 0.05-0.1% Tween-20 in antibody dilution buffers to reduce background

• Detection and Analysis:

  • Choose detection method based on expected expression level and required sensitivity

  • Document exposure settings and implement consistent image acquisition parameters

  • Use quantitative analysis software with appropriate normalization to loading controls

Recent research emphasizes that knockout cell line controls provide the strongest validation for Western blot experiments, outperforming other control methods . Including these controls is essential for confirming antibody specificity.

How does MATP expression correlate with melanoma progression and what methodological considerations apply?

When investigating MATP expression in melanoma progression using MATP7 Antibody, researchers should implement rigorous methodological approaches to ensure reliable results:

• Sample Selection and Processing:

  • Analyze matched normal tissue, primary tumors, and metastatic samples when possible

  • Document tumor staging, patient demographics, and treatment history

  • Standardize tissue processing and preservation methods

  • Consider tissue microarrays for high-throughput analysis with consistent staining conditions

• Expression Analysis Methods:

  • Implement multi-modal detection (IHC, WB, qPCR) for comprehensive expression profiling

  • Develop standardized scoring systems for immunohistochemistry with clear positive/negative thresholds

  • Use digital image analysis software to quantify staining intensity and cellular distribution

  • Correlate protein expression with genomic and transcriptomic data when available

• Technical Considerations:

  • Melanin pigment can interfere with chromogenic detection methods; consider fluorescence-based alternatives

  • Include appropriate melanocyte markers (MART-1, S100) for cell type identification

  • Implement batch controls to account for staining variability between experiments

  • Use appropriate statistical methods for correlation analysis with clinical parameters

• Validation Approaches:

  • Verify findings across multiple patient cohorts

  • Correlate expression patterns with functional assays (proliferation, invasion)

  • Consider single-cell approaches to address tumor heterogeneity

  • Validate findings in cell line models representing different melanoma stages

What approaches can overcome technical challenges when using MATP7 Antibody in immunoprecipitation studies?

Immunoprecipitation (IP) with MATP7 Antibody presents unique challenges due to MATP's membrane localization. Implementing the following methodological approaches can enhance success:

• Optimized Lysis Strategies:

  • Test multiple detergent formulations (digitonin, CHAPS, DDM) to identify optimal solubilization while preserving native structure

  • Implement low-temperature procedures throughout to minimize protein degradation

  • Consider crosslinking approaches for transient protein interactions

  • Pre-clear lysates thoroughly using protein A/G beads to reduce non-specific binding

• Antibody-Bead Coupling:

  • Determine optimal antibody-to-bead ratio through titration experiments (typically 2-5 μg antibody per 20 μl bead slurry)

  • Consider covalent coupling of antibody to beads using crosslinkers to prevent antibody co-elution

  • Pre-block beads with irrelevant protein (BSA) to reduce non-specific binding

  • Implement appropriate negative controls (isotype control antibody, non-expressing cells)

• Incubation Parameters:

  • Extend antibody-lysate incubation time (overnight at 4°C) to maximize target capture

  • Optimize lysate concentration and volume to antibody ratio

  • Maintain gentle agitation during incubation (rotation rather than shaking)

  • Consider sequential IPs to increase purity

• Washing and Elution Strategies:

  • Develop optimized wash buffers balancing stringency against complex preservation

  • Implement multiple wash steps with decreasing detergent concentrations

  • For interactome studies, consider native elution with competing peptides

  • For western blot analysis, use reducing sample buffer with appropriate heating

• Verification Methods:

  • Confirm target pull-down efficiency by western blotting small aliquots

  • Consider mass spectrometry for unbiased interactome analysis

  • Verify key interactions through reciprocal IPs

  • Implement biological replicates to establish reproducibility

Recent research has highlighted the value of well-characterized antibodies in IP applications, with recombinant antibodies generally outperforming traditional monoclonal antibodies in consistency and specificity . This is particularly relevant for challenging targets like membrane proteins.

How should researchers design experiments to study MATP regulation by MITF?

MATP expression is transcriptionally regulated by MITF (microphthalmia-associated transcription factor), a melanocyte-specific transcription factor . Designing rigorous experiments to investigate this regulatory relationship requires:

• Expression Correlation Studies:

  • Analyze MITF and MATP expression across multiple melanoma cell lines

  • Implement time-course experiments following MITF modulation

  • Use both protein (MATP7 Antibody) and mRNA (qRT-PCR) measurements

  • Quantify expression using appropriate normalization controls

• Transcriptional Regulation Analysis:

  • Perform chromatin immunoprecipitation (ChIP) to detect MITF binding to MATP promoter

  • Develop luciferase reporter constructs with wild-type and mutated MITF binding sites

  • Use CRISPR-based approaches to modify endogenous MITF binding sites

  • Implement MITF silencing and overexpression systems

• Functional Validation:

  • Assess phenotypic consequences of disrupting MITF-MATP regulatory axis

  • Analyze pigmentation changes in relevant melanocyte models

  • Evaluate impact on proliferation, migration, and invasion in melanoma models

  • Investigate potential feedback mechanisms between MATP and MITF

• Technical Controls and Validation:

  • Include non-MITF regulated genes as controls

  • Verify antibody specificity using methods described in section 2.1

  • Implement rescue experiments to confirm specificity of observed effects

  • Correlate findings with patient sample data when available

This experimental framework enables comprehensive characterization of the MITF-MATP regulatory relationship, providing insights into both normal melanocyte biology and potential dysregulation in melanoma contexts. The inclusion of appropriate controls is essential given concerns about antibody reliability in the research community .

What methodology should be used to quantify MATP expression changes in experimental models?

Accurate quantification of MATP expression changes requires careful methodology selection and implementation:

• Western Blot Quantification:

  • Implement standard curves using recombinant MATP protein or calibrated cell lysates

  • Ensure detection system operates within linear dynamic range

  • Use appropriate loading controls (preferably other membrane proteins of similar abundance)

  • Employ image analysis software with background subtraction and normalization features

  • Report fold changes relative to control conditions with appropriate statistical analysis

• Flow Cytometry Quantification:

  • Develop optimized fixation and permeabilization protocols for membrane protein detection

  • Use calibration beads to standardize fluorescence intensity measurements

  • Report results as median fluorescence intensity (MFI) with appropriate statistics

  • Consider dual staining with cell type-specific markers

  • Implement isotype controls and fluorescence-minus-one (FMO) controls

• qPCR Methodology:

  • Design primers spanning exon-exon junctions to prevent genomic DNA amplification

  • Validate primer efficiency using standard curves

  • Select appropriate reference genes verified for stability in your experimental system

  • Use multiple reference genes for normalization when possible

  • Implement biological and technical replicates with appropriate statistical analysis

• Immunohistochemistry Quantification:

  • Develop standardized scoring systems with clear definitions

  • Use digital pathology tools for objective quantification

  • Implement machine learning approaches for unbiased analysis when possible

  • Report both intensity and distribution parameters

  • Validate scoring methodology with multiple independent observers

Each methodology offers distinct advantages and limitations. Western blotting provides information about protein size and potential modifications, flow cytometry enables single-cell analysis, qPCR offers high sensitivity for transcript detection, and immunohistochemistry provides spatial context. A multi-method approach provides the most comprehensive analysis of MATP expression changes.

How can researchers effectively use MATP7 Antibody in co-localization studies?

Co-localization studies to determine MATP's subcellular distribution and potential interaction partners require specialized methodology:

• Sample Preparation Optimization:

  • Test multiple fixation methods (paraformaldehyde, methanol, acetone) to preserve epitope accessibility

  • Optimize permeabilization conditions specifically for membrane proteins

  • Consider mild detergents (0.01-0.1% saponin, digitonin) that preserve membrane structure

  • Implement antigen retrieval methods when necessary for fixed tissues

• Antibody Selection and Validation:

  • Verify MATP7 Antibody specificity using knockout controls

  • Select co-staining antibodies from different host species to prevent cross-reactivity

  • Validate all antibodies individually before attempting co-localization

  • Include single-stain controls to establish appropriate imaging parameters

• Imaging Methodology:

  • Employ confocal microscopy for optimal spatial resolution

  • Consider super-resolution techniques (STED, STORM) for detailed membrane localization

  • Use sequential scanning to minimize channel bleed-through

  • Acquire z-stacks to capture three-dimensional distribution

  • Implement consistent laser power and detector settings across samples

• Quantitative Analysis:

  • Use specialized co-localization software (JACoP, Coloc2) for objective analysis

  • Calculate appropriate co-localization coefficients (Pearson's, Manders')

  • Implement intensity correlation analysis for quantitative assessment

  • Establish thresholds based on control samples

  • Report statistical significance across multiple cells and experiments

• Validation Strategies:

  • Correlate imaging results with biochemical fractionation

  • Confirm key co-localization findings with proximity ligation assay (PLA)

  • Verify with electron microscopy for precise subcellular localization

  • Implement FRET or BRET approaches for direct interaction assessment

These methodological considerations are essential for generating reliable co-localization data, especially considering recent findings highlighting concerns about antibody specificity in the research community . Thorough validation using the approaches detailed in section 2.1 should precede co-localization studies.

What strategies can resolve non-specific binding issues with MATP7 Antibody?

Non-specific binding presents a common challenge when working with antibodies against membrane proteins like MATP. Implementing a systematic troubleshooting approach can resolve these issues:

• Blocking Optimization:

  • Test alternative blocking agents (5% BSA, 5% normal serum, commercial blockers)

  • Extend blocking duration (2-3 hours at room temperature or overnight at 4°C)

  • Add mild detergents to blocking buffer (0.1-0.3% Triton X-100, 0.05-0.1% Tween-20)

  • Consider specialized blockers for membrane proteins (e.g., fish gelatin)

• Antibody Conditions:

  • Titrate antibody concentration to identify optimal signal-to-noise ratio

  • Reduce primary antibody incubation temperature (4°C)

  • Extend incubation time with more dilute antibody solutions

  • Pre-absorb antibody with non-expressing cell lysates to remove cross-reactive antibodies

  • Add competing proteins (BSA, normal serum) to antibody dilution buffer

• Washing Protocol Adjustments:

  • Increase wash buffer stringency (150-500 mM NaCl)

  • Extend washing duration and frequency

  • Include detergents in wash buffers (0.1-0.5% Tween-20)

  • Consider chaotropic agents at low concentrations for stubborn background

  • Implement temperature-controlled washing (cold or warm depending on background type)

• Sample-Related Modifications:

  • Further purify protein samples when possible

  • Use freshly prepared samples to minimize degradation

  • Implement additional blocking steps for endogenous biotin, peroxidases, or phosphatases

  • Consider alternative lysis methods that may reduce interfering components

• Validation Methods:

  • Perform peptide competition assays to identify specific versus non-specific signals

  • Use knockout or knockdown controls to definitively identify specific bands

  • Test alternative detection systems that may provide better signal-to-noise ratio

Recent studies have shown that approximately 50% of commercial antibodies fail to meet basic standards for characterization , highlighting the importance of thorough validation and optimization for each specific application.

How should researchers interpret and address unexpected bands in Western blots using MATP7 Antibody?

Unexpected bands in Western blots using MATP7 Antibody require systematic investigation to determine their nature and significance:

• Potential Causes and Analysis Methods:

• Experimental Verification Approaches:

  • Compare band patterns across multiple cell types with known MATP expression levels

  • Manipulate expression through overexpression or knockdown and observe band intensity changes

  • Perform immunoprecipitation followed by mass spectrometry to identify unexpected bands

  • Use alternative MATP antibodies targeting different epitopes to compare band patterns

  • Implement subcellular fractionation to determine localization of different immunoreactive species

• Reporting Considerations:

  • Document all observed bands with molecular weight markers

  • Clearly indicate which band(s) represent the target of interest

  • Include all relevant controls in publication figures

  • Describe optimization steps in methods sections

  • Consider including supplementary data showing antibody validation experiments

Recent research has revealed that approximately 12 publications per protein target included data from antibodies that failed to recognize the relevant target protein , highlighting the critical importance of thorough validation when unexpected bands are observed.

What are the best practices for storing and handling MATP7 Antibody to maintain optimal performance?

Proper storage and handling of MATP7 Antibody is essential for maintaining its specificity and sensitivity. Implementing these best practices can extend antibody lifespan and ensure consistent experimental results:

• Long-term Storage:

  • Store concentrated antibody stocks at -20°C or -80°C in small aliquots to minimize freeze-thaw cycles

  • Include cryoprotectants (30-50% glycerol) for freezer storage

  • Keep records of antibody lot numbers and dates of receipt/aliquoting

  • Monitor storage unit temperature stability with alarm systems

  • Consider adding preservatives (0.02% sodium azide) for refrigerated aliquots

• Working Solution Handling:

  • Prepare fresh working dilutions for each experiment when possible

  • Store diluted antibody at 4°C for short periods only (1-2 weeks maximum)

  • Add protein carriers (0.1-1% BSA) to dilute solutions to prevent adsorption to tubes

  • Use sterile techniques when handling antibody solutions to prevent microbial contamination

  • Avoid repeated freeze-thaw cycles of working dilutions

• Temperature Considerations:

  • Allow frozen aliquots to thaw completely at 4°C before use

  • Avoid exposing antibody to room temperature for extended periods

  • Centrifuge antibody vials briefly after thawing to collect liquid

  • Transport using appropriate cold chain measures

  • Never heat antibody solutions above 4°C unless specifically recommended

• Contamination Prevention:

  • Use sterile pipette tips and tubes when handling antibody

  • Avoid touching the inside of antibody container caps

  • Consider adding antimicrobial agents for long-term storage of working dilutions

  • Filter sterilize buffers used for antibody dilution

  • Monitor solutions for visible signs of contamination

• Performance Monitoring:

  • Include positive controls in each experiment to verify antibody functionality

  • Maintain reference blots/images from optimal antibody performance for comparison

  • Document antibody performance over time from the same lot

  • Test new lots against previous lots before depletion of existing stock

  • Consider functional testing before critical experiments if antibody has been stored for extended periods

These practices help maintain antibody functionality and experimental reproducibility, particularly important given the significant investment in both resources and research time that antibodies represent .

How can MATP7 Antibody be effectively utilized in translational cancer research?

MATP7 Antibody offers significant potential for translational cancer research, particularly in melanoma studies, given MATP's elevated expression in melanoma cell lines compared to normal tissues . Implementing these methodological approaches can maximize research impact:

• Biomarker Development Protocol:

  • Establish analytical validation using tissue microarrays with diverse melanoma subtypes

  • Determine sensitivity, specificity, reproducibility, and robustness metrics

  • Develop standardized scoring systems with clear positive/negative thresholds

  • Correlate expression with established prognostic factors and survival outcomes

  • Implement machine learning approaches for automated scoring when possible

• Therapeutic Target Assessment:

  • Evaluate MATP function through antibody-mediated neutralization studies

  • Investigate potential for antibody-drug conjugate development

  • Assess MATP expression changes following standard therapeutic interventions

  • Explore MATP in therapy resistance mechanisms

  • Correlate MATP expression with response to immunotherapy

• Combination with Emerging Technologies:

  • Integrate MATP analysis in spatial transcriptomics platforms

  • Develop multiplexed imaging protocols (mIF, Imaging Mass Cytometry)

  • Implement single-cell approaches to address tumor heterogeneity

  • Consider computational pathology approaches for large-scale analysis

  • Explore liquid biopsy applications if MATP fragments are detectable in circulation

• Clinical Correlation Methodology:

  • Design prospective tissue collection protocols with standardized processing

  • Implement matched primary/metastatic sampling when possible

  • Develop treatment-naïve and post-treatment comparison cohorts

  • Correlate with genomic profiling data

  • Address tumor microenvironment influences on MATP expression

Recent studies have demonstrated the importance of rigorous antibody validation in translational research , making the approaches detailed in section 2.1 particularly crucial when using MATP7 Antibody in clinical contexts.

What emerging methodologies show promise for enhancing MATP research using antibody-based approaches?

Emerging technologies offer opportunities to advance MATP research beyond traditional antibody applications:

• Proximity-Based Interaction Methods:

  • Proximity Ligation Assay (PLA) for detecting protein-protein interactions with spatial resolution

  • BioID or APEX2 proximity labeling combined with MATP7 Antibody for validation

  • FRET/FLIM microscopy for direct interaction assessment

  • Split-protein complementation assays for monitoring dynamic interactions

• Advanced Imaging Technologies:

  • Super-resolution microscopy (STORM, PALM, STED) for detailed membrane localization

  • Expansion microscopy for enhanced spatial resolution of membrane proteins

  • Light sheet microscopy for 3D tissue analysis

  • Intravital microscopy for in vivo dynamics when combined with fluorescently-tagged antibodies

• Single-Cell Analysis Platforms:

  • Mass cytometry (CyTOF) for high-dimensional protein profiling

  • Imaging mass cytometry for spatial proteomics

  • Microfluidic-based single-cell western blotting

  • Cyclic immunofluorescence for multiplexed protein detection

• Antibody Engineering Applications:

  • Nanobodies or single-chain antibody fragments for improved penetration

  • Bispecific antibodies targeting MATP and complementary markers

  • Photactivatable antibodies for targeted manipulation

  • Site-specific conjugation methods for improved homogeneity

• Computational and AI Approaches:

  • Machine learning for automated image analysis

  • Integrative multi-omics approaches combining antibody data with genomics/transcriptomics

  • Virtual screening for novel MATP-targeting compounds

  • Digital pathology platforms for large-scale MATP expression analysis

Recent advances in antibody technology have demonstrated that recombinant antibodies outperform traditional monoclonal and polyclonal antibodies in multiple applications , suggesting potential benefits in developing recombinant versions of MATP7 Antibody for enhanced performance.